23 de septiembre de 2020
30 de mayo de 2008
- Comunicado -

Tarceva(R) Delivers Benefits Across Broad Range of NSCLC Patients - Confirmed by New Data (y 2)

1. Allan S et al. Efficacy of erlotinib in patients with
advanced non-small cell lung cancer (NSCLC) relative to clinical
characteristics: subset analysis from the TRUST study. Poster
presented at ASCO 2008 Annual Meeting, Chicago, US.
2. IARC. GLOBOCAN 2002. Cancer incidence, Mortality and
Prevalence Worldwide.
3. F. Shepherd et al. Erlotinib in Previously Treated
Non-Small Cell Lung Cancer, A Trial of the National Cancer Institute
Of Canada Clinical Trials Group. N Engl J Med 2005; 353:123-32.
4. Lee J-S et al. FAST-ACT: a phase II randomized double-blind
trial of sequential erlotinib and chemotherapy as 1st-line treatment
in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
Abstract #8031: ASCO 2008 Annual Meeting, Chicago, US.

Contact Information For more information on TRUST and Tarceva or to arrange an interview with Dr Martin Reck, please contact: Lester B. Davis International Communications Manager, Tarceva, F. Hoffmann-La Roche Ltd, Direct: +41-61-688-20-78, Mobile: +41-79-618-76-73, E-Mail: lester.davis@roche.com ; May Baccari, Resolute Communications, Direct: +41-61-688-20-78, Mobile: +41-79-618-76-73, may.baccari@resolutecommunications.com .